

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/06, C11D 3/00 A61K 7/08	A1	(11) International Publication Number: WO 93/13750 (43) International Publication Date: 22 July 1993 (22.07.93)
--	----	---

(21) International Application Number: PCT/US93/00087

(22) International Filing Date: 7 January 1993 (07.01.93)

(30) Priority data:
07/819,397 10 January 1992 (10.01.92) US

(71) Applicant: ALLERGAN, INC. [US/US]; 2525 Dupont Drive, Post Office Box 19534, Irvine, CA 92713-9534 (US).


(72) Inventors: DING, Shulin ; 14641 Fir Avenue, Irvine, CA 92714 (US). TRAN, Thao, T. ; 13811 Euclid Street, Garden Grove, CA 92643 (US).

(74) Agents: VOET, Martin, A. et al.; Allergan, Inc., 2525 Dupont Drive, Post Office Box 19534, Irvine, CA 92713-9534 (US).

(81) Designated States: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).

Published*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: NONIRRITATING NONIONIC SURFACTANT COMPOSITIONS



(57) Abstract

A nonirritating, nonionic detergent surfactant composition suitable for application to and cleaning of sensitive tissue, including periocular and ocular tissue, having a low cytotoxicity and high cleaning ability includes a principal nonionic surfactant and at least one auxiliary nonionic surfactant present in the surfactant composition in sufficient amounts to increase the cleaning ability of the principal nonionic surfactant.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

WO 93/13750

PCT/US93/00087

-1-

NONIRRITATING NONIONIC SURFACTANT COMPOSITIONS

5 The present invention generally relates to
detergent surfactant compositions suitable for appli-
cation to and cleaning of sensitive tissues. More
particularly, the present invention relates to non-
irritating detergent surfactant compositions, com-
prised of a combination of nonirritating surfactants,
especially suitable for lid hygiene in the treatment
10 of chronic blepharitis.

 The blepharitis, or inflammation of the eyelid,
is a frequently encountered ocular disease. In
addition to causing red and itching eyes, blepharitis
15 may also interfere with the fitting of contact lenses,
as well as aggravate the treatment of keratitis sicca,
endanger intraocular surgery, or lead to corneal
complications, such as toxic ephitheat keratitis
catarrhal ulceration or phlyctenosis.

20 One common symptom of blepharitis is a heavy
deposition of oily debris called scurf on the eye-
lashes and lid margins. The oily debris is the
secretion (meibum) of meibomian glands. In the
25 blepharitis patients, it is often found that their
meibomian glands suffer from oversecretion and/or a
thickened meibum. As a result, the glands are en-
gorged, clogged and inflamed.

30 The meibum is composed of various classes of
lipids including a fatty wax/sterol ester fraction of
up to sixty percent. This lipid component can enhance
the accumulation of debris and crusting which further
exacerbates inflammation associated with the blepha-
35 ritis.

WO 93/13750

PCT/US93/00087

-2-

5 Lid hygiene is currently the most accepted
treatment for blepharitis. In addition, a number of
oral and topical medications may be utilized to
augment the primary lid hygiene therapy as may be
prescribed on an individual basis. Effective cleaning
agents for removal of meibomian secretions associated
with debris have been anionic surfactants having high
foaming characteristics. See, for example, U.S.
Patent No. 5,000,868.

10

Unfortunately, such anionic surfactants tend to
be irritating to sensitive ocular tissue and because
of their ionic nature, may be chemically incompatible
with other formulation ingredients such as, for
example, buffers, preservatives and medicaments.

15

Consequently, surfactant compositions, specifi-
cally formulated for lid hygiene, have required the
presence of surfactants capable of reducing the
irritant properties of the anionic surfactant or
reducing their chemical incompatibility.

20

The composition of the present invention, effec-
tive for use on periocular and ocular surface tissues
includes no component necessary for reducing irri-
tating characteristics of other surfactant components.

25

SUMMARY OF THE INVENTION

30

The present invention is a nonirritating deter-
gent surfactant composition suitable for application
to and cleaning of sensitive tissues which is espe-
cially effective for cleaning of ocular and periocular
tissue.

35

WO 93/13750

PCT/US93/00087

-3-

5

The composition comprises a principal nonionic surfactant present in the nonirritating detergent surfactant composition in a sufficient amount to clean the sensitive tissue. More particularly, the cleaning ability may be defined in terms of the lipid cleaning efficiency of the surfactant.

10

15

In addition, at least one auxiliary nonionic surfactant is present in the composition in a sufficient amount to increase the cleaning ability of the principal nonionic surfactant. It is important to appreciate that no irritating surfactants such as anionic surfactants are present in the composition of the present invention. Hence, there is no component of the composition of the present invention which is added to overcome or suppress the irritating activity of a component. This results in a naturally inherent nonirritating surfactant composition.

20

25

30

Importantly, the auxiliary surfactants present in the composition are effective for enhancing the cleaning ability of the principal auxiliary nonionic surfactant. In the instance where one auxiliary surfactant is used in conjunction with the principal nonionic surfactant, the cleaning ability of the resultant composition is greater than the cleaning ability of either the principal surfactant or the auxiliary surfactant taken alone. More particularly, this occurs when both the principal and auxiliary nonionic surfactants comprise block polymers of polyoxyethylene and polyoxypropylene. Specifically, this enhanced cleaning activity occurs when the principal nonionic surfactant comprises Pluronic® P85, (CTFA name: poloxamer 235) and the auxiliary nonionic

WO 93/13750

PCT/US93/00087

-4-

surfactant comprises Pluronic® F87 (CTFA name: poloxamer 237).

5 The nonirritating detergent surfactant composition of the present invention further has extremely low irritation potential to ocular and periocular tissue. The low irritation potential of the composition of the present invention may be demonstrated with
10 in vitro Chinese hamster ovary cell cytotoxicity test. Specifically, when the principal and auxiliary non-ionic surfactants are present in the nonirritating detergent surfactant composition in a combined amount of at most ten percent by weight, and the composition
15 applied to Chinese hamster ovary cells at a tenfold dilution, more than eighty percent of the cells survive.

BRIEF DESCRIPTION OF THE DRAWINGS

20 The advantages and features of the present invention will be better understood by the following description when considered in conjunction with the accompanying drawings in which:

25 Figure 1 is a three-dimensional representation showing the relative cleaning ability of compositions in accordance with the present invention having varying amounts of principal and auxiliary nonionic surfactants; and

30 Figure 2 is a plot of relative survival of Chinese hamster ovary cells for the present invention, either unpreserved or preserved by five different preservative systems, showing the cytotoxicity profile thereof. The profile of an unpreserved anionic

WO 93/13750

PCT/US93/00087

-5-

surfactant, disodium monolaureth sulfosuccinate, is also included for comparison.

DETAILED DESCRIPTION

5

It has been well established that a surfactant which cleans better is usually more damaging to cells. For example, anionic surfactants are generally more efficient in removing grease and dirt but are also more irritating and have a high cytotoxicity profile.

10

Nonionic surfactants are known to be milder than anionic surfactants but heretofore have not demonstrated detergent activity on a par with anionic surfactants.

15

As hereinbefore briefly discussed, prior art formulations for lid hygiene have utilized anionic surfactants which have high cytotoxicity and irritation to sensitive surfaces. In combination with such ionic surfactants, a number of components have been utilized in an attempt to reduce the irritant properties of the ionic surfactants. Because of the inherent irritant activity of anionic surfactants, compositions incorporating such surfactants, even though compensating components are present, require complete and thorough rinsing of the compositions from ocular and periocular tissue due to the possibility of anionic surfactant remaining in contact with such tissue after use of surfactant and thereby causing high irritation.

20

25

30

In view of the fact that no component of the composition of the present invention is inherently irritating to periocular or ocular tissue, no rinsing

35

WO 93/13750

PCT/US93/00087

-6-

of the composition following lid cleaning is required.

5 While the following description of the present invention is directed to use as cleansers for ocular and periocular tissue, because of its nonirritating and low cytotoxicity profile, the composition of the present invention is also suitable for the cleaning of skin, mucous membranes, wounds, contact lenses, and removal of makeup for eyes and facial tissue. In addition, its use may be extended to the cleaning of hands and fingers which would subsequently be in contact with eyes, wounds, or other sensitive areas.

15 The principal nonionic surfactant present in the composition of the present invention is a block copolymer of polyoxyethylene and polyoxypropylene which are available under the trade name Pluronic® marketed by BASF. Specifically, the principal non-ionic surfactant is Pluronic® P85. A first auxiliary nonionic surfactant is also a block copolymer of polyoxyethylene and polyoxypropylene and specifically comprises Pluronic® F87. The principal surfactant is present in the composition in an amount from about four percent to about nine percent by weight.

25 The first auxiliary surfactant is added to enhance the cleaning ability of the principal surfactant which may be effected through better solubilization, emulsification, or wetting power. The preferred auxiliary surfactant, in accordance with the present invention, Pluronic® F87 is present in the composition in an amount from about 0.5 percent to about two percent by weight.

WO 93/13750

PCT/US93/00087

-7-

5 Preferably, a second auxiliary nonionic surfactant, such as ethoxylated octyl phenol, may be combined with the principal and first auxiliary surfactants. Specifically, the second auxiliary surfactant may be Igepal® CA 897 (CTFA name: octoxynol 40) marketed by Rhone-Poulenc.

10 Preferably, the total amount of surfactants in the composition of the present invention is ten percent or less of the total composition with the remaining component being water. It should be appreciated that the composition of the present invention may be buffered by any common buffer system such as phosphate, borate, acetate, and citrate with the pH and osmolarity adjusted in accordance with well-known techniques to proper physiological values.

15 In addition, if a preservative is desired, the compositions may be preserved with any well-known system such as benzyl alcohol with/without EDTA, benzalkonium chloride, chlorhexidine, Cosmocil® CQ, or Dowicil® 200.

20 Importantly, because of the nonionic nature of the surfactants of the present invention, no chemical incompatibility is encountered even if a positively or negatively charged preservative is incorporated, such as quaternary ammonium salts. This also applies to buffers and other medicaments that may be used in combination with the composition of the present invention.

25 In addition, depending upon the use of the cleanser, amino acids, minerals, vitamins, or the like may be added to provide nutrition to skin or tissues.

WO 93/13750

PCT/US93/00087

-8-

Further, moisturizers or emollients such as aloglycerine propylene glycol, hyaluronic acid, hydroxic propyl cellulose, or carboxy methyl cellulose may be added to soothe the skin. Specifically, when the composition is to be used in connection with cleaning wounds, medications may be added, such as antibiotics, antimicrobiocidal agents, anti-inflammatory agents, local anesthetics, anti-acne agents, etc., depending upon the specific activity desired.

10

A clear advantage of the present invention resides not only in its extremely low toxicity risk but also in its minimal chemical incompatibility with other ingredients (such as preservatives, buffers, medications, etc.) incorporated in the formulations. The minimal chemically incompatible risk is attributed to the position of no ionizable functional groups in the surfactants chosen in the present invention.

15

20

The cleaning ability, specifically the lipid cleaning ability, of the composition of the present invention is diagrammatically presented in Figure 1 so as to illustrate the synergistic effect of nonionic surfactant combinations which, in the case of Pluronic® F87 and Pluronic® P85, results in a greater cleaning ability than the cleaning ability of either the Pluronic® F87 or P85 taken separately. In addition, as will be hereinafter demonstrated, the combination of the principal surfactant, Pluronic® P85, and auxiliary surfactants, Pluronic® F87 and octoxynol 40, provide lipid cleaning ability on a par with anionic surfactants but with no irritating properties and significantly less cytotoxicity.

25

30

WO 93/13750

PCT/US93/00087

-9-

5 The diagram as shown in Figure 1 will be discussed in more detail after the following description of the protocol in determining the cleaning ability of the detergent surfactant in accordance with the present invention.

10 In order to show lipid cleaning ability of the composition of the present invention, an artificial lipid mixture was utilized which comprised thirty percent cholesteryl stearate, thirty-five percent lanolin, and thirty-five percent Miglyol® 810 (CTFA name: caprylic/capric triglyceride).

15 This mixture was supported on a polymacon (38/0) lens (Hydron) with the convex surface of the lens coated with the artificial lipid mixture by lightly touching the surface to the melted lipid and leaving the coated lens on a slide (convex surface facing up), for between ten to thirty minutes.

20 Thereafter, the composition to be tested was placed, five drops at a time, on the palm of a hand and the lens, with the convex surface facing down, rubbed in a circular motion in the composition for twenty seconds. Thereafter, the lipid remaining on the lens was officially observed.

25 The cleaning efficacy scoring system was as follows:

30

WO 93/13750

PCT/US93/00087

-10-

CLEANING EFFICACY TEST

SCORE	VISUAL OBSERVATION (after rubbing lens with tested composition)
0	Lens is totally coated with lipid
1	1/6 of the lens is not covered by lipid
2	1/3 of the lens is not covered by lipid
3	1/2 of the lens is not covered by lipid
4	2/3 of the lens is not covered by lipid
5	5/6 of the lens is not covered by lipid
6	All lipid on the lens is gone

The cleaning score, between 1 and 6, is plotted for various surfactant compositions in Figure 1 for percentages of principal surfactant from 0 to 10%, first auxiliary surfactant from 0 to 10%, and second auxiliary surfactant from 0 to 10%. The remaining composition is water.

These number scores appear in Figure 1, which is diagrammatically presented in order to show the increased cleaning ability of the composition when the primary surfactant Pluronic® P85 is between about 2% to about 9%, the first auxiliary surfactant Pluronic® F87 is present in the amount of between .5% to about 2%, and the second auxiliary surfactant octoxynol 10 is present in the amount of about 0.5% to about 5%. Each of the points displayed in Figure 1 include a total surfactant weight of about 10%. To compare the composition of the present invention with the prior art lid hygiene formulations, the cleaning efficacy test, as hereinabove described, was performed on I-Scrub, distributed by Spectra. The results are shown hereinbelow:

WO 93/13750

PCT/US93/00087

-11-

TEST SOLUTION	OBSERVED SCORE
Spectra's I-Scrub	4.67, 5.33, 5, 4.67, 5.33 Mean=5.0, CV=6.6%
The optimized formulation	5.3, 5

These results demonstrate that the optimized formulation of the present invention has the equivalent cleaning ability as that of I-Scrub, which is an anionic surfactant-based formulation.

The ingredients of I-Scrub are generally known as follows:

I-SCRUB

Disodium monolaureth Sulfosuccinate	anionic surfactant (mild, high foaming)
PEG-200 Glyceryl Monotallowate	nonionic surfactant (emulsifier, anti-irritant)
PEG-78 Glyceryl Monococoate	nonionic surfactant (emulsifier, anti-irritant)
Cocoamidopropylamine Oxide	nonionic surfactant (foam booster, anti-irritant)
Benzyl Alcohol, EDTA, Purified Water USP	preservative

An important feature of the composition of the present invention is its low cytotoxicity profile. The cytotoxicity was evaluated as follows to quantify chemically-induced toxicity. Chinese hamster ovary cells used (CHO) are a well-characterized cell line and are widely used in cytotoxicity assays as has been well-documented in the literature.

The materials and methods of the present assay are as follows:

MATERIALS

WO 93/13750

PCT/US93/00087

-12-

A. CHEMICALS AND MEDIA

1. Ham's F-12 medium (1X, with sodium bicarbonate)
2. Heat inactivated fetal bovine serum (lots tested using SOP TC-003)
3. L-glutamine solution (200 mM)
4. Dulbecco's phosphate buffered saline (PBS)
5. Trypsin-EDTA solution (1X)
6. Sodium chloride
7. Sodium phosphate (monobasic and dibasic)
8. β -nicotinamide adenine dinucleotide phosphate (NADP)
9. Glucose-6-phosphate (Glc-6-P)
10. Potassium chloride
11. Magnesium chloride
12. Calcium chloride
13. Aroclor 1254 induced rat liver S9
14. Methanol
15. Giemsa stain

B. Tissue Culture Supplies and Cell Lines

1. Tissue culture dishes (6-well clusters)
2. Chinese hamster ovary (CHO) cells, clone K₁-BH₄ (originally from Oakridge National Laboratory)

METHODS

A. Preparation

1. Media for cell growth (Ham's F-12)
 - a. Add 50 ml of heat inactivated fetal bovine serum per 500 ml Ham's F-12 medium.
 - b. Add 2.5 ml of glutamine per 500 ml medium.
2. Liver 59 - cofactors mix

WO 93/13750

PCT/US93/00087

-13-

- 5 a. Prepare stock solutions of: 0. M sodium phosphate, pH 8.0; 0.1 M NADP; 1.0 M glc-6-P; 1.5 M potassium chloride; 0.5 M magnesium chloride; and 0.5 M calcium chloride.
- 10 b. Prepare sterile 8.8 ml cofactor mix aliquots containing: 5.45 ml double distilled water; 2.5 ml sodium phosphate; 0.4 ml NADP; 0.05 ml glc-6-P; 0.2 ml potassium chloride; and 0.2 ml magnesium chloride. These aliquots can be stored frozen at -70°C.
- 15 c. Prior to use, thaw aliquot cofactor mix and add 0.2 ml calcium chloride. A white precipitate will form.
- d. Add 1 ml of liver S9 (-30 mg/ml) to the cofactor mix and store on ice.
- B. Cytotoxicity Assay
- 20 1. Trypsinize CHO cells using the procedures described in Research Microbiology SOP TC-001.
2. Determine cell concentration using one of the procedures outlined in Research Microbiology SOP TC-002.
- 25 3. Dilute the cell suspension to a final concentration of 100 cells per ml in complete growth media. Maintain the cell suspension on ice until cells are plated to minimize cellular attachment to the surfaces of the container.
- 30 4. Pipet 2 ml of the cell suspension into each well (200 cells/well). Shake the dish in two directions immediately after filling all of the wells in the dish. This is critical to ensure even distribution of cells
- 35

WO 93/13750

PCT/US93/00087

-14-

throughout the entire surface area of the dish.

5. Allow the cells to attach for 3 hours at $37^{\circ} \pm 1^{\circ}\text{C}$ in a humidified incubator with an atmosphere of 5% CO_2 in air.
6. At the time of treatment, change medium to 2 ml Ham's F-12 medium (with glutamine, without serum).
7. For assays designed to measure the effect of metabolic activation, add 0.4 ml of S9-cofactors mixture to 1.6 ml of Ham's F-12 (with glutamine, without serum) at the time of treatment.
8. Add test compound in 20 μl of ethanol, acetone or DMSO (1% v/v final concentration of solvent) depending on solubility. Note: DMSO also facilitates cellular uptake. If the test compound is a suspension (such as liposomes) they can be added in up to 100 μl of PBS. Three wells are used per dose.
9. Each assay must include positive and negative controls. The equivalent volume of the solvent alone serves as the negative control. Any known cytotoxic agents at cytotoxic doses can be used as positive controls (e.g., cyclohexamide, mitomycin C, benzo (a) pyrene).
10. Return dishes to the incubator for 3 hours. Do not stack the dishes more than two high as it is important for sample cultures to stabilize at $37^{\circ} \pm 1^{\circ}\text{C}$ at the same time. This is even more critical for experiments involving S9 since the reaction kinetics for the enzymes involved in metabolic activation are temperature dependent.

WO 93/13750

PCT/US93/00087

-15-

11. Remove medium containing test compound out of each well and rinse surface with 1 ml of PBS per well.
12. Pipet 2 ml of complete growth medium (Ham's F-12, with serum and glutamine) into each well.
13. Return dishes to incubator and allow cells to grow for 7-8 days. Do not handle dishes as this minimizes colony splitting.
14. Fix, stain and score colonies as described in Research Microbiology SOP TC-005.
15. Express cytotoxicity data as cloning efficiency (C.E.) and relative survival (R.S.).

$$\text{C.E.} = \frac{\text{number of colonies}}{\text{number of cells plated (200)}}$$

$$\text{R.S.} = \frac{\text{C.E. treated}}{\text{C.E. solvent control}}$$

The results of the cytotoxicity assay or cytotoxicity profile are shown in Figure 2, which shows the relative survival of the Chinese hamster ovary cells as a function of concentration of the formulation tested.

The hereinabove-described CHO clonal assay was used to establish the cytotoxicity profiles for the present invention preserved by five different preservative systems. Ten to one hundredfold dilutions of these solutions were tested, with all dilutions being made in distilled water. The unpreserved present invention was also tested. The vehicle, water in this case, was used as a positive control. The relative cell survival is calculated by comparing the cells surviving from a formulation with the cells surviving from water. Disodium monolaureth sulfosuccinate, a "mild" anionic surfactant commonly used in baby

WO 93/13750

PCT/US93/00087

-16-

shampoos and lid hygiene products, was used as a negative control. The solutions tested were as follows:

- 5 1. Pluronic® P85/Pluronic® F87/octoxynol 40
 (7:1:2 ratio) 10% solution
2. Pluronic® P85/Pluronic® F87/octoxynol 40
 (7:1:2 ratio) 10% solution + Benzyl Alcohol
 (0.5%)
- 10 3. Pluronic® P85/Pluronic® F87/octoxynol 40
 (7:1:2 ratio) 10% solution + Benzyl Alcohol
 (0.5%) + EDTA (0.05%)
4. Pluronic® P85/Pluronic® F87/octoxynol 40
 (7:1:2 ratio) 10% solution + Benzyl Alcohol
15 (0.5) + Germall 115 (0.3%)
5. Pluronic® P85/Pluronic® F87/octoxynol 40
 (7:1:2 ratio) 10% solution + Dowicil® 200
 (0.03%) - Phosphate Buffer
6. Disodium monolaureth sulfosuccinate
- 20

The results dramatically show the low cytotoxicity of the formulations in accordance with the present invention. For example, at concentrations of up to 10% of the unpreserved formulation in accordance with the present invention, an 80% relative survival is shown, which is roughly 100 fold less cytotoxic than the "mild" surfactant, disodium monolaureth sulfosuccinate. The preserved formulations, depending on the preservative system used, may be 30 to 100 fold less cytotoxic than disodium monolaureth sulfosuccinate. Therefore, because of the low cytotoxicity of the formulations in accordance with the present invention, the formulation need not be rinsed, or flushed, from the eye after instillation.

WO 93/13750

PCT/US93/00087

-17-

5

This is to be compared with prior art products comprising anionic surfactants which must, because of their relatively high cytotoxicity, be rinsed, or removed, from the eye after instillation because residual anionic surfactant will cause eye irritation.

10

Hence, it can be readily appreciated that the low cytotoxicity of the formulation of the present inventions eliminates the criticality of rinsing.

15

That is, if some, or all, of the formulation of the present invention remains in the eye, little, if any, irritation occurs, due to the nonionic surfactants therein.

20

In addition, it is shown that a formulation in accordance with the present invention which is preserved with benzyl alcohol exhibited a cytotoxicity profile similar to the unpreserved solution at 10% of formulation. Also, the addition of EDTA did not significantly alter the cytotoxicity profile of the formulation at 10%.

25

Other formulations of various preservatives exhibited a lower cytotoxicity profile.

30

The formulation of the present invention may be produced in any conventional manner by combining the surfactants in the proportions hereinabove recited.

35

Although there has been hereinabove described a nonirritating detergent surfactant composition suitable for application in cleaning of sensitive tissues such as periocular and ocular tissues, in accordance with the present invention, for the purpose of illus-

WO 93/13750

PCT/US93/00087

-18-

trating the manner in which the invention may be used
to advantage, it should be appreciated that the
invention is not limited thereto. Accordingly, any
and all modifications, variations, or equivalent
arrangements which may occur to those skilled in the
art, should be considered to be within the scope of
the present invention as defined in the appended
claims.

5

1769

10

15

20

25

30

35

WO 93/13750

PCT/US93/00087

-19-

WHAT IS CLAIMED IS:

1. A nonirritating detergent surfactant composition suitable for application to and cleaning of sensitive tissue, said nonirritating detergent surfactant composition comprising:

5

a principal nonionic surfactant present in said nonirritating detergent surfactant composition in a sufficient amount to clean said sensitive tissue; and

10

at least one auxiliary nonionic surfactant present in said nonirritating detergent surfactant composition in a sufficient amount to increase the cleaning ability of the principal nonionic surfactant.

5

2. The nonirritating detergent surfactant composition according to Claim 1 wherein the cleaning ability of the nonirritating detergent surfactant composition is greater than the cleaning ability of each of the principal and auxiliary nonionic surfactants.

3. The nonirritating detergent surfactant composition according to Claim 2 wherein said principal and auxiliary nonionic surfactants comprise block copolymers of polyoxyethylene and polyoxypropylene.

4. The nonirritating detergent surfactant composition according to Claim 3 wherein the principal nonionic surfactant comprises Pluronic® P85 and the auxiliary nonionic surfactant comprises Pluronic® F87.

WO 93/13750

PCT/US93/00087

-20-

5. The nonirritating detergent surfactant composition according to Claim 1 or 2 wherein the cleaning ability is the lipid cleaning efficiency of the surfactants.

5 6. The nonirritating detergent surfactant composition according to Claim 1 comprising two auxiliary nonionic surfactants present in said non-irritating detergent surfactant composition in amounts sufficient to increase the cleaning ability of the principal nonionic surfactant.

7. The nonirritating detergent surfactant composition according to Claim 6 wherein said principal surfactant comprises a block copolymer of polyoxyethylene and polyoxypropylene.

5 8. The nonirritating detergent surfactant composition according to Claim 7 wherein a first of said two auxiliary nonionic surfactants comprises a block copolymer of polyoxyethylene and polyoxypropylene.

9. The nonirritating detergent surfactant composition according to Claim 8 wherein a second of said two auxiliary nonionic surfactants comprises an ethoxylated octyl phenole.

5 10. The nonirritating detergent surfactant composition according to Claim 9 wherein the principal nonionic surfactant is Pluronic® P85, the first auxiliary nonionic surfactant is Pluronic® F87, and the second auxiliary nonionic surfactant is octoxynol 40.

WO 93/13750

PCT/US93/00087

-21-

11. The nonirritating detergent surfactant composition according to Claim 10 wherein said Pluronic® P85 is present in an amount of about 0.5% to about 9.5% by weight, and Pluronic® F87 is present in an amount of from 0% to about 2.5% by weight and said octoxynol 40 is present in an amount of about 0% to about 9.5% by weight, and the total weight percent of the Pluronic® P85, Pluronic® F87, and octoxynol 40 is about 10% by weight of the nonirritating detergent surfactant composition.

12. The nonirritating detergent surfactant composition according to Claim 11 wherein said Pluronic® P85 is present in an amount by weight of about 7%, and Pluronic® F87 is present in an amount by weight of about 1% and said octoxynol 40 is present in an amount by weight of about 2%.

13. A nonirritating detergent surfactant composition having low cytotoxicity for ocular and periocular tissue, said nonirritating detergent surfactant composition comprising:

a principal nonionic surfactant present in said nonirritating detergent surfactant composition in a sufficient amount to clean ocular and periocular tissue; and
at least one auxiliary nonionic surfactant present in said nonirritating detergent surfactant composition in a sufficient amount to increase the cleaning ability of the principal nonionic surfactant.

14. The nonirritating detergent surfactant composition according to Claim 13 wherein the cleaning

WO 93/13750

PCT/US93/00087

-22-

5 ability of the nonirritating detergent surfactant composition is greater than the cleaning ability of each of the principal and auxiliary nonionic surfactants.

15. The nonirritating detergent surfactant composition according to Claim 13 or 14 wherein the cleaning ability is the lipid cleaning efficiency of the surfactants.

5 16. The nonirritating detergent surfactant composition according to Claim 13 or 14 wherein said principal and auxiliary nonionic surfactants are present in said nonirritating detergent surfactant composition in a combined amount of at most 10% by weight and when applied to Chinese hamster ovary cells, more than 80% of the cells survive at ten fold dilution in distilled water.

5 17. The nonirritating detergent surfactant composition according to Claim 13 comprising two auxiliary nonionic surfactants present in said nonirritating detergent surfactant composition in amounts sufficient to increase the cleaning ability of the principal nonionic surfactant.

18. The nonirritating detergent surfactant composition according to Claim 17 wherein said principal surfactant comprises a block copolymer of polyoxyethylene and polyoxypropylene.

19. The nonirritating detergent surfactant composition according to Claim 18 wherein a first of said two auxiliary nonionic surfactants comprises a

WO 93/13750

PCT/US93/00087

-23-

5 block copolymer of polyoxyethylene and
polyoxypropylene.

20. The nonirritating detergent surfactant composition according to Claim 19 wherein a second of said two auxiliary nonionic surfactants comprises an ethoxylated octyl phenole.

5 21. The nonirritating detergent surfactant composition according to Claim 20 wherein the principal nonionic surfactant is Pluronic® P85, the first auxiliary nonionic surfactant is Pluronic® F87, and the second auxiliary nonionic surfactant is octoxynol 40.

5 22. The nonirritating detergent surfactant composition according to Claim 21 wherein said Pluronic® P85 is present in an amount of about 2% to about 9% by weight, and Pluronic® F87 is present in an amount of about 0.5% to about 2% by weight and said octoxynol 40 is present in an amount of about 0.5% to about 5% by weight, and the total weight percent of the Pluronic® P85, Pluronic® F87, and octoxynol 40 is about 10% by weight of the nonirritating detergent
10 surfactant composition.

5 23. The nonirritating detergent surfactant composition according to Claim 22 wherein said Pluronic® P85 is present in an amount by weight of about 7%, and Pluronic® F87 is present in an amount by weight of about 1% and said octoxynol 40 is present in an amount by weight of about 2%.

24. The nonirritating detergent surfactant composition according to Claim 21 wherein said

WO 93/13750

PCT/US93/00087

-24-

Pluronic® P85, Pluronic® F87 and octoxynol 40 are present in an amount by weight sufficient to obtain an observed cleaning score, by the procedure set forth in the accompanying specification, of more than 5.0.

25. A nonirritating detergent surfactant composition having low cytotoxicity for ocular and periocular tissue, said nonirritating detergent surfactant composition comprising:

a principal nonionic surfactant present in said nonirritating detergent surfactant composition in a sufficient amount to clean ocular and periocular tissue; and

at least one auxiliary nonionic surfactant present in said nonirritating detergent surfactant composition in a sufficient amount to increase the cleaning ability of the principal nonionic surfactant,

said principal and auxiliary nonionic surfactants enabling the combination of the surfactant composition with positively or negatively charged preservatives, buffers and medicaments without chemical incompatibility.

26. A method of cleaning ocular and periocular tissue comprising the steps of instilling in an eye a composition comprising a principal nonionic surfactant present in said composition in a sufficient amount to clean ocular and periocular tissue and at least one auxiliary nonionic surfactant present in said compo-

WO 93/13750

PCT/US93/00087

-25-

sition in a sufficient amount to increase the cleaning ability of the principal nonionic surfactant, and thereafter allowing said composition to remain in the eye.

27. A method of cleaning ocular and periocular tissue comprising the steps of instilling in an eye a composition comprising a principal nonionic surfactant present in said composition in a sufficient amount to clean ocular and periocular tissue and at least one auxiliary nonionic surfactant present in said composition in a sufficient amount to increase the cleaning ability of the principal nonionic surfactant, and thereafter rinsing only a portion of the composition from the eye.

28. The method in accordance with claim 27 wherein the composition comprises two auxiliary nonionic surfactants present in said composition in amounts sufficient to increase the cleaning ability of the principal nonionic surfactant.

29. The method in accordance with claim 28 wherein said principal surfactant comprises Pluronic® P85, a first auxiliary nonionic surfactant comprises Pluronic® F87 and a second auxiliary nonionic surfactant comprises octoxynol 40.

30. The method in accordance with claim 29 wherein said Pluronic® P85 is present in an amount of about 2% to about 9% by weight, said Pluronic® F87 is present in the composition in an amount of about 0.5% to about 2% by weight and said octoxynol 40 is present in said composition in an amount of about 0.5% to about 5% by weight and the total weight percent of the

WO 93/13750

PCT/US93/00087

-26-

Pluronic® P85, Pluronic® F87 and octoxynol 40 is about 10% by weight of the composition.

WO 93/13750

PCT/US93/00087

1/2





FIG. 1.

WO 93/13750

PCT/US93/00087

2/2

FIG. 2.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/00087

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 A61K9/06; C11D3/00; A61K7/08

II. FIELDS SEARCHEDMinimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl. 5

A61K ; A61L ; C11D

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸**III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹**

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claims No. ¹³
X	EP,A,0 240 464 (CIBA GEIGY AG) 7 October 1987 see page 2, column 2, line 9 - line 21 see page 3, column 4, line 20 - line 49 see page 5; example 12 ---	1,5,7, 13,15,18
X	EP,A,0 076 136 (ALCON LABORATORIES INC) 6 April 1983 see page 14; example 8 see page 14, line 31 - page 15, line 6 ---	1,3,5,7, 8,13,15
X	FR,A,2 515 201 (TOYO CONTACT LENS CO LTD) 29 April 1983 see page 5, line 4 - line 28 see page 6, line 29 - line 33 see page 6 - page 7; example 1 see claims 1,2 --- -/-	1,7

¹⁰ Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

19 APRIL 1993

Date of Mailing of this International Search Report

11 2 93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

BOULOIS D.

PCT/US 93/00087

International Application No

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category ^a	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	EP,A,0 439 429 (CIBA GEIGY AG) 31 July 1991 see page 3, line 33 - line 44 see page 5, line 12 - line 20 see page 6; example 8 see claims 1,2 ---	1,5,13
A	EP,A,0 406 695 (TOMEI KABUSHIKI KAISHA) 9 January 1991 see page 9; example 8 see claim 1 ---	1
A	EP,A,0 079 185 (SMITH & NEPHEW ASSOCIATED COMPANIES PLC) 18 May 1983 see page 7, line 1 - line 14 see page 14; example 1 -----	1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/00087

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7-30
because they relate to subject matter not required to be searched by this Authority, namely:
Method of treatment of the human body, see PCT RULE 39.1(IV)

Although claim 26 is directed to a method of treatment of the human body the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 9300087
SA 69031

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19/04/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0240464	07-10-87	US-A- 4734222	29-03-88
		AU-A- 7093387	08-10-87
		JP-A- 62242916	23-10-87
EP-A-0076136	06-04-83	US-A- 4407791	04-10-83
		AU-B- 557817	08-01-87
		AU-A- 9050382	08-04-83
		CA-A- 1194421	01-10-85
		WO-A- 8301003	31-03-83
		US-A- 4525346	25-06-85
FR-A-2515201	29-04-83	JP-C- 1525264	12-10-89
		JP-A- 58070208	26-04-83
		JP-B- 63063885	08-12-88
		DE-A, C 3238820	05-05-83
		GB-A, B 2108699	18-05-83
		US-A- 4440662	03-04-84
EP-A-0439429	31-07-91	AU-A- 6934491	01-08-91
		JP-A- 4313721	05-11-92
EP-A-0406695	09-01-91	JP-A- 3041412	21-02-91
EP-A-0079185	18-05-83	US-A- 4504405	12-03-85